Review



nipocalimab m281  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress nipocalimab m281
    Inhibition of endocytotic albumin and IgG uptake by the FcRn-blocking antibody <t>nipocalimab.</t> ASCs remained untreated or were preincubated for 2 h with different doses of nipocalimab (5, 15, 25 μg/mL), and the intracellular content of either Alexa-594 albumin ( n = 6) ( a ) or IgG ( n = 6) ( b ) was monitored after 1 h of incubation. Intracellular IgG was visualized by labeling with an anti IgG antibody conjugated with Alexa Fluor 488. Scale bars represent 10 μm. * , ** , *** p < 0.05, 0.01, 0.001 as compared to the untreated sample. c , d Inhibition of Ca 2+ oscillations by nipocalimab (25 μg/mL). c Untreated ASCs in serum-containing complete ASC cell culture medium. d Nipocalimab-treated sample. Shown are representative traces derived from n = 12 experiments.
    Nipocalimab M281, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nipocalimab m281/product/MedChemExpress
    Average 93 stars, based on 5 article reviews
    nipocalimab m281 - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "Endocytotic Albumin Uptake Pathways in Human Adipose Stem Cells and Connection to Intracellular Calcium Oscillations and the Neonatal Fc receptor"

    Article Title: Endocytotic Albumin Uptake Pathways in Human Adipose Stem Cells and Connection to Intracellular Calcium Oscillations and the Neonatal Fc receptor

    Journal: Cells, Tissues, Organs

    doi: 10.1159/000545773

    Inhibition of endocytotic albumin and IgG uptake by the FcRn-blocking antibody nipocalimab. ASCs remained untreated or were preincubated for 2 h with different doses of nipocalimab (5, 15, 25 μg/mL), and the intracellular content of either Alexa-594 albumin ( n = 6) ( a ) or IgG ( n = 6) ( b ) was monitored after 1 h of incubation. Intracellular IgG was visualized by labeling with an anti IgG antibody conjugated with Alexa Fluor 488. Scale bars represent 10 μm. * , ** , *** p < 0.05, 0.01, 0.001 as compared to the untreated sample. c , d Inhibition of Ca 2+ oscillations by nipocalimab (25 μg/mL). c Untreated ASCs in serum-containing complete ASC cell culture medium. d Nipocalimab-treated sample. Shown are representative traces derived from n = 12 experiments.
    Figure Legend Snippet: Inhibition of endocytotic albumin and IgG uptake by the FcRn-blocking antibody nipocalimab. ASCs remained untreated or were preincubated for 2 h with different doses of nipocalimab (5, 15, 25 μg/mL), and the intracellular content of either Alexa-594 albumin ( n = 6) ( a ) or IgG ( n = 6) ( b ) was monitored after 1 h of incubation. Intracellular IgG was visualized by labeling with an anti IgG antibody conjugated with Alexa Fluor 488. Scale bars represent 10 μm. * , ** , *** p < 0.05, 0.01, 0.001 as compared to the untreated sample. c , d Inhibition of Ca 2+ oscillations by nipocalimab (25 μg/mL). c Untreated ASCs in serum-containing complete ASC cell culture medium. d Nipocalimab-treated sample. Shown are representative traces derived from n = 12 experiments.

    Techniques Used: Inhibition, Blocking Assay, Incubation, Labeling, Cell Culture, Derivative Assay



    Similar Products

    nipocalimab m281  (MedChemExpress)
    93
    MedChemExpress nipocalimab m281
    Inhibition of endocytotic albumin and IgG uptake by the FcRn-blocking antibody <t>nipocalimab.</t> ASCs remained untreated or were preincubated for 2 h with different doses of nipocalimab (5, 15, 25 μg/mL), and the intracellular content of either Alexa-594 albumin ( n = 6) ( a ) or IgG ( n = 6) ( b ) was monitored after 1 h of incubation. Intracellular IgG was visualized by labeling with an anti IgG antibody conjugated with Alexa Fluor 488. Scale bars represent 10 μm. * , ** , *** p < 0.05, 0.01, 0.001 as compared to the untreated sample. c , d Inhibition of Ca 2+ oscillations by nipocalimab (25 μg/mL). c Untreated ASCs in serum-containing complete ASC cell culture medium. d Nipocalimab-treated sample. Shown are representative traces derived from n = 12 experiments.
    Nipocalimab M281, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nipocalimab m281/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    nipocalimab m281 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    nipocalimab m281 antibody  (Momenta Pharma)
    90
    Momenta Pharma nipocalimab m281 antibody
    Inhibition of endocytotic albumin and IgG uptake by the FcRn-blocking antibody <t>nipocalimab.</t> ASCs remained untreated or were preincubated for 2 h with different doses of nipocalimab (5, 15, 25 μg/mL), and the intracellular content of either Alexa-594 albumin ( n = 6) ( a ) or IgG ( n = 6) ( b ) was monitored after 1 h of incubation. Intracellular IgG was visualized by labeling with an anti IgG antibody conjugated with Alexa Fluor 488. Scale bars represent 10 μm. * , ** , *** p < 0.05, 0.01, 0.001 as compared to the untreated sample. c , d Inhibition of Ca 2+ oscillations by nipocalimab (25 μg/mL). c Untreated ASCs in serum-containing complete ASC cell culture medium. d Nipocalimab-treated sample. Shown are representative traces derived from n = 12 experiments.
    Nipocalimab M281 Antibody, supplied by Momenta Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nipocalimab m281 antibody/product/Momenta Pharma
    Average 90 stars, based on 1 article reviews
    nipocalimab m281 antibody - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    nipocalimab m281  (Janssen)
    90
    Janssen nipocalimab m281
    Approved and clinical late-stage FcRn antagonists
    Nipocalimab M281, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nipocalimab m281/product/Janssen
    Average 90 stars, based on 1 article reviews
    nipocalimab m281 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    mcx3cr1 m281 mice  (MedChemExpress)
    93
    MedChemExpress mcx3cr1 m281 mice
    Approved and clinical late-stage FcRn antagonists
    Mcx3cr1 M281 Mice, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mcx3cr1 m281 mice/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    mcx3cr1 m281 mice - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    nipocalimab/m281  (Janssen)
    90
    Janssen nipocalimab/m281
    Approved and clinical late-stage FcRn antagonists
    Nipocalimab/M281, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nipocalimab/m281/product/Janssen
    Average 90 stars, based on 1 article reviews
    nipocalimab/m281 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    nipocalimab (m281)  (Momenta Pharma)
    90
    Momenta Pharma nipocalimab (m281)
    Investigational monoclonal antibodies in late-stage clinical studies for non-cancer indications*
    Nipocalimab (M281), supplied by Momenta Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nipocalimab (m281)/product/Momenta Pharma
    Average 90 stars, based on 1 article reviews
    nipocalimab (m281) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    nipocalimab m281  (Momenta Pharma)
    90
    Momenta Pharma nipocalimab m281
    Investigational monoclonal antibodies in late-stage clinical studies for non-cancer indications*
    Nipocalimab M281, supplied by Momenta Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nipocalimab m281/product/Momenta Pharma
    Average 90 stars, based on 1 article reviews
    nipocalimab m281 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Inhibition of endocytotic albumin and IgG uptake by the FcRn-blocking antibody nipocalimab. ASCs remained untreated or were preincubated for 2 h with different doses of nipocalimab (5, 15, 25 μg/mL), and the intracellular content of either Alexa-594 albumin ( n = 6) ( a ) or IgG ( n = 6) ( b ) was monitored after 1 h of incubation. Intracellular IgG was visualized by labeling with an anti IgG antibody conjugated with Alexa Fluor 488. Scale bars represent 10 μm. * , ** , *** p < 0.05, 0.01, 0.001 as compared to the untreated sample. c , d Inhibition of Ca 2+ oscillations by nipocalimab (25 μg/mL). c Untreated ASCs in serum-containing complete ASC cell culture medium. d Nipocalimab-treated sample. Shown are representative traces derived from n = 12 experiments.

    Journal: Cells, Tissues, Organs

    Article Title: Endocytotic Albumin Uptake Pathways in Human Adipose Stem Cells and Connection to Intracellular Calcium Oscillations and the Neonatal Fc receptor

    doi: 10.1159/000545773

    Figure Lengend Snippet: Inhibition of endocytotic albumin and IgG uptake by the FcRn-blocking antibody nipocalimab. ASCs remained untreated or were preincubated for 2 h with different doses of nipocalimab (5, 15, 25 μg/mL), and the intracellular content of either Alexa-594 albumin ( n = 6) ( a ) or IgG ( n = 6) ( b ) was monitored after 1 h of incubation. Intracellular IgG was visualized by labeling with an anti IgG antibody conjugated with Alexa Fluor 488. Scale bars represent 10 μm. * , ** , *** p < 0.05, 0.01, 0.001 as compared to the untreated sample. c , d Inhibition of Ca 2+ oscillations by nipocalimab (25 μg/mL). c Untreated ASCs in serum-containing complete ASC cell culture medium. d Nipocalimab-treated sample. Shown are representative traces derived from n = 12 experiments.

    Article Snippet: Subconfluent live ASCs were incubated with nipocalimab (M281) (MedChemExpress, cat. No. HY-P99037) at concentrations of 5, 15 and 25 μg/mL.

    Techniques: Inhibition, Blocking Assay, Incubation, Labeling, Cell Culture, Derivative Assay

    Approved and clinical late-stage FcRn antagonists

    Journal: Antibody Therapeutics

    Article Title: Structure and function of therapeutic antibodies approved by the US FDA in 2023

    doi: 10.1093/abt/tbae007

    Figure Lengend Snippet: Approved and clinical late-stage FcRn antagonists

    Article Snippet: Nipocalimab (M281) , Janssen R&D (Momenta) , Phase 3 (NCT05912517) , MG, HDFN, RA, SLE, wAIHA , Human IgG1λ R120K, N296A, ΔK445 , IV infusion Q2W , [ , ] .

    Techniques:

    Investigational monoclonal antibodies in late-stage clinical studies for non-cancer indications*

    Journal: mAbs

    Article Title: Antibodies to watch in 2021

    doi: 10.1080/19420862.2020.1860476

    Figure Lengend Snippet: Investigational monoclonal antibodies in late-stage clinical studies for non-cancer indications*

    Article Snippet: Momenta Pharmaceuticals , Nipocalimab (M281) , Human IgG1 , FcRn , Phase 2/3 , Warm autoimmune hemolytic anemia (NCT04119050).

    Techniques: Bioprocessing, Virus, Infection